Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Pfizer
Pfizer
Stanford University
Jonsson Comprehensive Cancer Center
xCures
University of Nebraska
Adela, Inc
Eli Lilly and Company
Degron Therapeutics Co.
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
The University of Texas Health Science Center at San Antonio
M.D. Anderson Cancer Center
Ikena Oncology
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Azienda Ospedaliera di Padova
Apollomics Inc.
Columbia University
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Children's Hospitals and Clinics of Minnesota
Universidade Federal de Pernambuco
Taproot Health
VitaMed Research LLC
ABM Therapeutics Corporation
UNICANCER
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Hoffmann-La Roche
Roswell Park Cancer Institute
Celgene
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
AHS Cancer Control Alberta
Memorial Sloan Kettering Cancer Center
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fox Chase Cancer Center
National Cancer Institute (NCI)